Evidence brief
Epitalon
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
No FDA-approved epitalon drug product.
A four-amino-acid peptide promoted for sleep and longevity. Its evidence has identity-transfer problems and no established insomnia or lifespan outcome evidence.
- How strong is the evidence?
- Insufficient
Reliable studies in people are missing, too limited, or do not support the claim. This does not prove that the substance has no effect on the body. - What evidence exists?
- Preclinical or formulation evidence
The research used cells, animals, or product-form tests. It does not establish benefit or safety in people. - Sports rules
- Not assessed
No current sports-rule review is available.
Reviewed July 23, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as Epithalon · AEDG · epitalon acetate
Words used here
- peptide
- a short chain of amino acids
- outcome
- what the study measured
- preclinical
- research in cells, tissues, or animals before or outside testing in people
- formulation
- the ingredients and physical form of the finished product
- route
- how the product enters the body
- mechanism
- how a substance may cause a body change
- biomarker
- a body or lab measurement, not automatically a health benefit
- randomized
- assigned to study groups by chance
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
FDA found no studies establishing insomnia outcomes for the nominated epitalon substances and route.
Melatonin and cell-line findings are indirect and do not establish patient benefit.
Human product, route, exposure, impurity, and long-term safety data are inadequate.
Evidence often mixes epitalon, epitalon acetate, and non-identical pineal preparations.
02 · Identity
What it is
Epitalon is a four-amino-acid peptide: Ala-Glu-Asp-Gly. It is often discussed with epithalamin, a pineal preparation, but they are not the same intervention.
Scientific group: Synthetic tetrapeptide. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
None identified in the United States.
- No FDA-approved indication
04 · Research results
What the research shows
Laboratory work has reported telomere-related effects in human cell lines. Telomeres are protective ends of chromosomes. FDA's current review found melatonin-related information but no clinical insomnia studies using the nominated substances by the proposed route.
Changes in cells grown in a laboratory do not establish slower aging, longer life, cancer prevention, or improved health in people. Evidence from epithalamin cannot be reassigned to epitalon.
Exact product
Similar names do not mean that products have the same evidence. Epitalon, epitalon acetate, and older pineal extracts such as epithalamin are not automatically interchangeable evidence objects.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“Epitalon changes telomere biology in human cell lines.”
A 2025 laboratory study reported telomere-length effects in cultured human cell lines.
- Evidence used
- Preclinical evidence. This answer uses research in cells, animals, or other settings outside patient care. It does not show a benefit in people.
- Limits of this answer
- Cultured cell lines, not health outcomes in treated people. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Epitalon is proven to treat insomnia.”
FDA did not identify clinical insomnia studies of the nominated epitalon substances by the proposed route.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- Adults with insomnia assessed using clinical sleep outcomes. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Epitalon has been proven to extend human lifespan.”
The evidence does not provide reliable product-specific randomized lifespan outcomes for epitalon.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- Human lifespan and healthspan outcomes attributable to epitalon. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Epitalon
No FDA-approved epitalon drug product. No approved product is identified in the United States.
Not assessed. This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body. This status is not personal clearance to compete.
Laboratory work has reported telomere-related effects in human cell lines. Telomeres are protective ends of chromosomes. FDA's current review found melatonin-related information but no clinical insomnia studies using the nominated substances by the proposed route.
Changes in cells grown in a laboratory do not establish slower aging, longer life, cancer prevention, or improved health in people. Evidence from epithalamin cannot be reassigned to epitalon.
07 · Safety
Safety limits for this record
A claim about longer life needs long-term results in people, not only laboratory mechanisms. This guide provides no injectable, sleep-treatment, or anti-aging regimen.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
No current sports-rule review is available.
Reviewed .Check current rules for tested sport ↗08 · Sources
Read the sources
09 · Review history
Review history
Initial brief reflects FDA's July 2026 insomnia-focused evidence review before final agency action.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.